- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC
November 8th 2024, 7:59pm
Co-formulated vibostolimab and pembrolizumab plus chemotherapy failed to improve OS in the first line vs atezolizumab plus chemotherapy in ES-SCLC.
PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC
November 8th 2024, 7:45pm
The biomarker analysis of patients enrolled on part B of the CheckMate 914 trial explored the effects of PD-L1 and KIM-1 expression.
Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors
November 8th 2024, 7:31pm
Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
November 7th 2024, 8:46pm
DK210 (EGFR) showed evidence of wild-type IL-2 signaling, CRS mitigation, and immune response signaling in patients with solid tumors.
Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors
November 7th 2024, 8:18pm
Siglec-15 was expressed in tumor cells and tumor-associated macrophages in tissue samples from non–small cell lung cancer and other solid tumors.
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
November 7th 2024, 7:30pm
Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors
November 7th 2024, 6:10pm
The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.
42nd Annual CFS Preview for Medical Oncologists: The Show and After Show
November 7th 2024, 3:59pm
OncLive co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.
Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma
November 1st 2024, 7:00pm
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Casdatifan was well tolerated and had durable clinical activity in patients with metastatic clear cell renal cell carcinoma.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
October 29th 2024, 4:46pm
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
October 28th 2024, 7:55pm
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
The first-in-class CDK8/19 inhibitor RVU120 demonstrated early signs of clinical activity in patients with relapsed/refractory metastatic or advanced solid tumors.
RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer
October 28th 2024, 5:28pm
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
October 25th 2024, 8:00pm
Treatment with APR-1051 appears safe and well tolerated in patients with advanced solid tumors and select cancer-associated gene alterations.
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
October 25th 2024, 4:03pm
TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
October 17th 2024, 12:00pm
Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.
MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma
October 11th 2024, 1:01pm
MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.
PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma
October 9th 2024, 1:00pm
Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.
Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer
October 8th 2024, 6:53pm
The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.
Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC
October 6th 2024, 10:00am
Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.
MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma
October 2nd 2024, 10:52pm
International Myeloma Society Annual Meeting
MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.